个人简介
2002年本科毕业于湖南中医学院(现湖南中医药大学)中药学专业,后在该校继续深造,2005年获得硕士学位。2012年6月毕业于中山大学,获药物化学博士学位,后进入中山大学科恩伯格团队从事博士后研究工作,并于2013年赴韩国延世大学进行短期学术访问。现为广州医科大学药学院讲师,主要从事小分子化合物与蛋白质的复合物晶体研究工作。目前已在国内外期刊及学术会议上发表研究论文20余篇,其中SCI收录9篇。
研究领域
1.基于共晶结构的AKR1C3抑制剂研究。 2.新型抗前列腺癌药物分子设计。 3.已有药物的结构药理学研究
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
[1] Xuehua Zheng, Yinuo Wu, Deyan Wu, Xinhua Wang, Chao Zhang, Xiaolei Guo, Hai-Bin Luo*, 3D-QSAR studies of 3-(3,4-Dihydroisoquinolin-2(1H) -ylsulfonyl) benzoic acids as AKR1C3 inhibitors: Highlight the importance of molecular docking in conformation generation, BMC letters, 2016, 26(23): 5631-5638 [2] Xuehua Zheng, Liping Zhang, Weijia Chen, Yunyun Chen, Wei Xie, Xiaopeng Hu*, Partial inhibition of aldose reductase by nitazoxanide and its molecular basis, ChemMedChem, 2012, 7(11): 1921-1923 [3] Xuehua Zheng, Liping Zhang, Jing Zhai, Yunyun Chen, Haibin Luo*, Xiaopeng Hu*, The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase, FEBS Letters, 2012, 586(1): 55-59 [4] Liping Zhang, Hong Zhang, Yining Zhao, Zhe Li, Shangke Chen, Jing Zhai, Yunyun Chen, Wei Xie, Zhong Wang, Qing Li,; Xuehua Zheng*, Xiaopeng Hu*, Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111), FEBS Letters, 2013, 587(22): 3681-3686 [5] Xuehua Zheng, Yong-Xian Shao, Zhe Li, Ming Liu, Xianzhang Bu, Hai-Bin Luo*, Xiaopeng Hu*, Quantitative structure-retention relationship of curcumin and its analogues, J Sep Sci,2012, 35(4):505-512